These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 27163502

  • 21. Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine.
    Pesco-Koplowitz L, Hassell A, Lee P, Zhou H, Hall N, Wiesinger B, Mechlinski W, Grover M, Hunt T, Smith R, Travers S.
    J Clin Pharmacol; 1999 Jan; 39(1):76-85. PubMed ID: 9987703
    [Abstract] [Full Text] [Related]

  • 22. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [Abstract] [Full Text] [Related]

  • 23. The efficacy of fluticasone furoate administered in the morning or evening is comparable in patients with persistent asthma.
    Kempsford RD, Bal J, Baines A, Renaux J, Ravindranath R, Thomas PS.
    Respir Med; 2016 Mar; 112():18-24. PubMed ID: 26823210
    [Abstract] [Full Text] [Related]

  • 24. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study.
    Meltzer EO, Stahlman JE, Leflein J, Meltzer S, Lim J, Dalal AA, Prillaman BA, Philpot EE.
    Clin Ther; 2008 Feb; 30(2):271-9. PubMed ID: 18343265
    [Abstract] [Full Text] [Related]

  • 25. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [Abstract] [Full Text] [Related]

  • 26. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
    Matera MG, Capuano A, Cazzola M.
    Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
    [Abstract] [Full Text] [Related]

  • 27. Effect of intranasal fluticasone furoate and intraocular olopatadine on nasal and ocular allergen-induced symptoms.
    Baroody FM, Logothetis H, Vishwanath S, Bashir M, Detineo M, Naclerio RM.
    Am J Rhinol Allergy; 2013 Jan; 27(1):48-53. PubMed ID: 23406601
    [Abstract] [Full Text] [Related]

  • 28. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids.
    Bleecker ER, Bateman ED, Busse WW, Woodcock A, Frith L, House KW, Jacques L, Davis AM, Haumann B, Lötvall J.
    Ann Allergy Asthma Immunol; 2012 Nov; 109(5):353-358.e4. PubMed ID: 23062392
    [Abstract] [Full Text] [Related]

  • 29. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
    Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A.
    Thorax; 2012 Jan; 67(1):35-41. PubMed ID: 21828231
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 31. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [Abstract] [Full Text] [Related]

  • 32. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J, Kang J, Lee SH, Wang C, Zhou X, Crawford J, Jacques L, Stone S.
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [Abstract] [Full Text] [Related]

  • 33. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis.
    Gradman J, Caldwell MF, Wolthers OD.
    Clin Ther; 2007 Aug; 29(8):1738-47. PubMed ID: 17919555
    [Abstract] [Full Text] [Related]

  • 34. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
    Bleecker ER, Lötvall J, O'Byrne PM, Woodcock A, Busse WW, Kerwin EM, Forth R, Medley HV, Nunn C, Jacques L, Bateman ED.
    J Allergy Clin Immunol Pract; 2014 Aug; 2(5):553-61. PubMed ID: 25213048
    [Abstract] [Full Text] [Related]

  • 35. Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma.
    Calzetta L, Rinaldi B, Cazzola M, Matera MG.
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):813-22. PubMed ID: 27253498
    [Abstract] [Full Text] [Related]

  • 36. Fluticasone furoate: a new intranasal corticosteroid.
    Kumar R, Kumar D, Parakh A.
    J Postgrad Med; 2012 Jul; 58(1):79-83. PubMed ID: 22387656
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk.
    Meltzer EO, Lee J, Tripathy I, Lim J, Ellsworth A, Philpot E.
    Pediatr Allergy Immunol; 2009 May; 20(3):279-86. PubMed ID: 18680490
    [Abstract] [Full Text] [Related]

  • 38. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
    Kosoglou T, Hubbell J, Cutler DL, Johnson-Levonas AO, Xu D, Kantesaria BS, Kim K, Miller SD.
    Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095
    [Abstract] [Full Text] [Related]

  • 39. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays.
    Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C.
    Eur J Clin Pharmacol; 2004 Jun; 60(4):265-8. PubMed ID: 15114430
    [Abstract] [Full Text] [Related]

  • 40. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
    Ishiura Y, Fujimura M, Shiba Y, Ohkura N, Hara J, Kasahara K.
    Pulm Pharmacol Ther; 2015 Dec; 35():28-33. PubMed ID: 26497109
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.